List of Companies  

Agrum Foods India Pvt. Ltd.​​

• Business: B2B agri-supply chain – cold storage & food-grade potato starch.

• Strengths: Long-term PepsiCo & Cargill contracts, 97–98% utilization, integrated operations.

• Growth: Indian cold chain market CAGR 12.3%, global starch demand rising.

• Risks: Client concentration, potato price volatility, expansion execution.

• IPO View: Strong moat, stable cash flows; watch valuation & debt profile.​

RDP​

• Business: Affordable “Make in India” laptops/desktops, AI-ready hardware.

• Strengths: Underserved ₹30,000 Cr price segment, govt tender advantage.

• Growth: ₹78 Cr (FY25) → ₹1,000 Cr (FY29) target.

• Risks: Aggressive scaling, competition from global brands, capital-intensive.

• IPO View: High-growth electronics play; execution & funding discipline critical.​

Prabhu Naidu Ltd.

• Business: Vertically integrated recycled fabrics & eco-bags; ESG-focused.

• Strengths: Strong certifications, global clients, social impact (5,200+ rural women employed).

• Growth: 6.9× FY25 revenue jump; PAT CAGR >200%.

• Risks: Aggressive growth targets, working capital strain.

• IPO View: Attractive ESG + growth story if priced at 10–15× P/E.​

Alwar Greentech Ltd.

• Business: Lead oxides & alloys for industrial use.

• Strengths: Diverse products, experienced leadership, 44% revenue growth.

• Risks: Commodity price swings, environmental compliance.

• IPO View: Niche industrial play; attractive at 12–15× P/E.​

SRG Narrow Fab Ltd.

• Business: India’s largest elastic manufacturer (apparel, footwear, medical).

• Strengths: 30+ yrs ops, diversified demand, capacity expansion to 410 machines.

• Risks: Domestic market dependence, execution of expansion.

• IPO View: Stable niche with expansion upside; fair at ≤14× FY25 earnings.​

Inovit Solutions

• Business: Precision components for aerospace, defence, automotive, energy.

• Strengths: High-entry-barrier certifications, marquee clients, capacity for 6× growth.

• Risks: Sector concentration, aggressive projections.

• IPO View: Precision engineering + MRO potential; secure multi-year contracts pre-IPO.​

9M India Ltd.

• Business: Generic pharma with >1,000 approved products.

• Strengths: Regulatory edge in Chhattisgarh tenders, expansion into regulated markets.

• Growth: FY25–FY27 revenue to grow ~2.5×; high margins.

• Risks: Plant approval delays, tender concentration.

• IPO View: High-profitability, expansion-driven growth; fair at 18–20× P/E.